GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Minerva Neurosciences Inc (NAS:NERV) » Definitions » Intrinsic Value: Projected FCF

NERV (Minerva Neurosciences) Intrinsic Value: Projected FCF : $-38.89 (As of Dec. 16, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Minerva Neurosciences Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-12-16), Minerva Neurosciences's Intrinsic Value: Projected FCF is $-38.89. The stock price of Minerva Neurosciences is $2.21. Therefore, Minerva Neurosciences's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Minerva Neurosciences's Intrinsic Value: Projected FCF or its related term are showing as below:

NERV's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.365
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Minerva Neurosciences Intrinsic Value: Projected FCF Historical Data

The historical data trend for Minerva Neurosciences's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Neurosciences Intrinsic Value: Projected FCF Chart

Minerva Neurosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -48.33 -40.93 -48.15 -54.40 -43.30

Minerva Neurosciences Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.76 -43.30 -44.14 -44.04 -38.89

Competitive Comparison of Minerva Neurosciences's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Minerva Neurosciences's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minerva Neurosciences's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's Price-to-Projected-FCF falls into.



Minerva Neurosciences Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Minerva Neurosciences's Free Cash Flow(6 year avg) = $-28.07.

Minerva Neurosciences's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Sep24)/0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-28.07264+-21.671/0.8)/7.569
=-38.89

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Minerva Neurosciences  (NAS:NERV) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Minerva Neurosciences's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=2.21/-38.88890910648
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Minerva Neurosciences Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Minerva Neurosciences's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Minerva Neurosciences Business Description

Traded in Other Exchanges
Address
1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
Executives
Ag Boehringer 10 percent owner BINGER STRABE 173, INGELHEIM AM RHEIN 2M 55216
Boehringer Ingelheim International Gmbh 10 percent owner 200 PARK AVENUE, C/O KLAUS H JANDER ESQ ROGERS & WELLS LL, NEW YORK NY 10166
Remy Luthringer officer: EVP and Head of R&D C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Geoff Race officer: EVP and CFO C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Frederick W Ahlholm officer: Chief Accounting Officer C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Plc Barclays 10 percent owner 1 CHURCHILL PLACE, CANARY WHARF, LONDON X0 E14 5HP
David Kupfer director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Joseph H. Reilly officer: Chief Business Officer C/O MINERVA NEUROSCIENCES, 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Van Heek G Jan director ONE KENDALL SQUARE, CAMBRIDGE MA 02139
Richard E. Russell officer: President C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
William F Doyle director
Hans Peter Hasler director C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Index Venture Associates Iii Ltd 10 percent owner 5TH FLOOR, 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE1 3FG
Index Venture Associates Iv Ltd 10 percent owner 44 ESPLANADE, ST. HELIER, CHANNEL ISLANDS Y9 JE4 9WG

Minerva Neurosciences Headlines